| Vericel Corporation (VCEL) Q1 2025 Earnings Conference Call Transcript |
Vericel Corporation. (NASDAQ:VCEL ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Eric Burns - VP, Finance and IR Nick Colangelo - CEO Joe Mara - CFO Conference Call Participants Ryan Zimmerman - BTIG Richard Newitter - Truist Securities Josh Jennings - TD Cowen Caitlin Cronin - Canaccord Mason Carrico - Stephens Operator Thank you for standing by. |
seekingalpha.com |
2025-05-08 17:52:28 |
Czytaj oryginał (ang.) |
| Vericel Corporation (VCEL) Reports Q1 Loss, Misses Revenue Estimates |
Vericel Corporation (VCEL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.08 per share a year ago. |
zacks.com |
2025-05-08 14:05:44 |
Czytaj oryginał (ang.) |
| Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance |
Record First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 Million Approximately 400 MACI Arthro Surgeons Trained to Date, with Year-to-Date Biopsy Growth Over 30% for Trained Surgeons Second Quarter Total Revenue and MACI Revenue Growth Expected to be in the Low- to Mid-20% Range Full-Year 2025 Revenue Guidance Reaffirmed and Profitability Guidance Raised Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the first quarter ended March 31, 2025. |
globenewswire.com |
2025-05-08 11:55:00 |
Czytaj oryginał (ang.) |
| Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025 |
CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the Bank of America Securities 2025 Healthcare Conference at 12:20 p.m. ET (9:20 a.m. PT) on Wednesday, May 14, 2025. |
globenewswire.com |
2025-05-07 12:30:00 |
Czytaj oryginał (ang.) |
| Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025 |
CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2025 financial results on Thursday, May 8, 2025. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. |
globenewswire.com |
2025-04-24 12:30:00 |
Czytaj oryginał (ang.) |
| Vericel: Scalable Growth With Strong Margins |
Vericel's niche in regenerative medicine is undervalued, with FDA-approved products like MACI, Epicel, and NexoBrid driving steady revenue growth and profitability. The company's strong financials include $167 million in cash, zero debt, and a 16% year-over-year revenue increase, highlighting operational efficiency. MACI's expansion into ankle cartilage repair and a robust pipeline suggest significant future earnings potential, despite current market hesitations. |
seekingalpha.com |
2025-03-06 01:56:15 |
Czytaj oryginał (ang.) |
| Vericel to Present at Multiple Upcoming Investor Conferences |
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the following investor conferences: |
globenewswire.com |
2025-03-04 10:30:00 |
Czytaj oryginał (ang.) |
| Vericel Corporation (VCEL) Q4 2024 Earnings Conference Call Transcript |
Vericel Corporation (NASDAQ:VCEL ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Nick Colangelo - CEO Joe Mara - CFO Eric Burns - VP, Finance and IR Conference Call Participants Ryan Zimmerman - BTIG Mike Kratky - Leerink Partners Felipe Lamar - Truist Securities Josh Jennings - TD Cowen Caitlin Cronin - Canaccord Genuity Mason Carrico - Stephens, Inc. Jeffrey Cohen - Ladenburg Thalmann & Co. Swayampakula Ramakanth - H.C. Wainwright & Co. Operator Good day, and thank you for standing by. |
seekingalpha.com |
2025-02-27 15:05:17 |
Czytaj oryginał (ang.) |
| Vericel Corporation (VCEL) Tops Q4 Earnings Estimates |
Vericel Corporation (VCEL) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.30 per share. This compares to earnings of $0.26 per share a year ago. |
zacks.com |
2025-02-27 12:05:28 |
Czytaj oryginał (ang.) |
| Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results |
Full-Year Total Revenue Growth of 20% to $237.2 Million, with MACI Revenue Growth of 20% and Burn Care Revenue Growth of 22% |
globenewswire.com |
2025-02-27 09:54:00 |
Czytaj oryginał (ang.) |
| Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025 |
CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its fourth-quarter and full-year 2024 financial results on Thursday, February 27, 2025. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. |
globenewswire.com |
2025-02-13 10:30:00 |
Czytaj oryginał (ang.) |
| On The Hunt For Magnificent Earnings Growth? Check These 7 Stocks. |
None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth. |
investors.com |
2025-02-03 17:09:34 |
Czytaj oryginał (ang.) |
| Vericel (VCEL) Is a Great Choice for 'Trend' Investors, Here's Why |
Vericel (VCEL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. |
zacks.com |
2025-02-03 11:51:49 |
Czytaj oryginał (ang.) |
| Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session |
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Wednesday. |
benzinga.com |
2025-01-15 10:52:24 |
Czytaj oryginał (ang.) |
| Vericel Corporation: Hard To Justify Current Valuation |
Vericel Corporation, specializing in cellular therapies for sports medicine and severe burn care, has seen a 40% rise in its stock recently. Core products include MACI, NexoBrid, and Epicel, with Q3 revenues rising 27% year-over-year to $57.9 million, beating expectations. The company is turning the corner on profitability, but valuations look stretched at current trading levels. |
seekingalpha.com |
2024-12-19 14:50:29 |
Czytaj oryginał (ang.) |
| Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks. |
None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth. |
investors.com |
2024-12-03 18:20:34 |
Czytaj oryginał (ang.) |
| Here's Why Momentum in Vericel (VCEL) Should Keep going |
Vericel (VCEL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. |
zacks.com |
2024-11-11 11:51:18 |
Czytaj oryginał (ang.) |
| Vericel Corporation (VCEL) Q3 2024 Earnings Conference Call Transcript |
MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Eric Burns - Vice President of Finance & Investor Relations Nick Colangelo - Chief Executive Officer Joe Mara - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Richard Newitter - Truist Securities Mike Kratky - Leerink Partners Josh Jennings - TD Cowen Caitlin Cronin - Canaccord Jeffrey Cohen - Ladenburg Thalmann & Co. Operator Ladies and gentlemen, thank you for standing by. Welcome to Vericel's Third Quarter 2024 Conference Call. |
seekingalpha.com |
2024-11-07 15:52:06 |
Czytaj oryginał (ang.) |
| Vericel Corporation (VCEL) Reports Q3 Loss, Tops Revenue Estimates |
Vericel Corporation (VCEL) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago. |
zacks.com |
2024-11-07 12:11:09 |
Czytaj oryginał (ang.) |
| Vericel Reports Third Quarter 2024 Financial Results |
Total Revenue Growth of 27% to $57.9 Million Gross Margin of 72% and Adjusted EBITDA Growth of 84% Full-Year Profitability Guidance Raised FDA Approval and Commercial Launch of MACI Arthro in Third Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2024. |
globenewswire.com |
2024-11-07 09:55:00 |
Czytaj oryginał (ang.) |
| Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024 |
CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2024 financial results on Thursday, November 7, 2024. Vericel's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights. |
globenewswire.com |
2024-10-24 12:30:00 |
Czytaj oryginał (ang.) |
| Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024 |
CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference at 1:05 p.m. ET on Friday, September 6, 2024. |
globenewswire.com |
2024-08-29 13:17:00 |
Czytaj oryginał (ang.) |
| Vericel Announces FDA Approval and Commercial Availability of MACI Arthro |
First Restorative Biologic Cartilage Repair Product Approved for Arthroscopic Administration Targets the Largest Segment of MACI's $3 Billion Addressable Market CAMBRIDGE, Mass., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) expanding the MACI® (autologous cultured chondrocytes on porcine collagen membrane) label to include arthroscopic delivery of MACI to repair symptomatic single or multiple full-thickness cartilage defects of the knee up to 4 cm2 in size. |
globenewswire.com |
2024-08-26 11:45:00 |
Czytaj oryginał (ang.) |
| Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns |
Approval Expands NexoBrid Target Customer Base to Include Approximately 20 Pediatric Burn Centers CAMBRIDGE, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Food and Drug Administration (FDA) has approved a pediatric indication for NexoBrid® (anacaulase-bcdb) for eschar removal in pediatric patients with deep partial-thickness and/or full-thickness thermal burns. |
globenewswire.com |
2024-08-15 20:05:00 |
Czytaj oryginał (ang.) |
| Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024 |
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Growth Conference at 3:00 p.m. ET on Wednesday, August 14, 2024. |
globenewswire.com |
2024-08-07 12:30:00 |
Czytaj oryginał (ang.) |
| What Makes Vericel (VCEL) a New Strong Buy Stock |
Vericel (VCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
zacks.com |
2024-08-05 17:01:19 |
Czytaj oryginał (ang.) |
| Vericel Corporation (VCEL) Q2 2024 Earnings Call Transcript |
Vericel Corporation (NASDAQ:VCEL ) Q2 2024 Results Conference Call August 1, 2024 8:30 AM ET Company Participants Eric Burns - Vice President of Finance & Investor Relations Nick Colangelo - Chief Executive Officer Joe Mara - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Mike Kratky - Leerink Partners Josh Jennings - TD Cowen Jeff Cohen - Ladenburg Thalmann & Company Swayampakula Ramakanth - HCW Operator Ladies and gentlemen, thank you for standing by. Welcome to Vericel's Second Quarter 2024 Conference Call. |
seekingalpha.com |
2024-08-01 19:58:11 |
Czytaj oryginał (ang.) |
| Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates |
Vericel Corporation (VCEL) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.11 per share a year ago. |
zacks.com |
2024-08-01 14:06:15 |
Czytaj oryginał (ang.) |
| Vericel Reports Second Quarter 2024 Financial Results |
Total Revenue of $52.7 Million, with MACI Revenue Growth of 21% to $44.1 Million NexoBrid Revenue Growth of 76% Over Prior Quarter Gross Margin of 70% and Adjusted EBITDA Growth of 42% Full-Year Profitability Guidance Raised to 71% Gross Margin and 21% Adjusted EBITDA Margin Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2024. |
globenewswire.com |
2024-08-01 11:55:00 |
Czytaj oryginał (ang.) |
| Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer |
CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, who served as Vericel's Head of Human Resources since September 2010. |
globenewswire.com |
2024-07-22 12:30:00 |
Czytaj oryginał (ang.) |
| Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024 |
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2024 financial results on Thursday, August 1, 2024. Vericel's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights. |
globenewswire.com |
2024-07-18 12:30:00 |
Czytaj oryginał (ang.) |
| The 3 Highest-Rated Medical Stocks You Can Buy Today |
The medical field is a non-negotiable aspect of society. Advanced healthcare is required to combat existing diseases and protect ourselves from new ones. |
investorplace.com |
2024-06-27 18:03:15 |
Czytaj oryginał (ang.) |
| Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024 |
CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Truist Securities MedTech Conference at 2:30 p.m. ET on Tuesday, June 18, 2024. |
globenewswire.com |
2024-06-11 12:30:00 |
Czytaj oryginał (ang.) |
| Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024 |
CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference at 9:40 a.m. ET on Wednesday, May 29, 2024. |
globenewswire.com |
2024-05-22 12:30:00 |
Czytaj oryginał (ang.) |